Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRD205 for Postoperative Analgesia After Hallux Valgus Surgery
NCT07121023Phase 1Not yet recruiting
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TRD205 in postoperative pain (4 arms), sponsored by Beijing Tide Pharmaceutical Co., Ltd. Primary endpoint: Treatment-Related Adverse Events at 5 days. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
TRD205
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07121023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121023.